ENDRA Life Sciences reported earnings of per NDRA share on Nov 13, 2026, falling short of analysts' expectations by
| Report Date | Nov 13, 2026 |
|---|---|
| Forecasted EPS | -$ 0.84 |
| Last Year's EPS | -$ 2.33 |
| EPS YoY Change |
Out of the last 47 earnings reporting periods, ENDRA Life Sciences beat analysts’ expectations 14 times and fell short of expectations 16 time(s). ENDRA Life Sciences reported earnings per share of in the last report surpassing an estimated EPS of -$ 0.84 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 0.84 | -$ 1.71 | - | |
| Aug 14, 2026 | -$ 0.84 | -$ 0.63 | -$ 2.59 | |
| May 18, 2026 | -$ 1.23 | -$ 1.09 | -$ 9.40 | |
| Mar 31, 2026 | -$ 1.23 | -$ 3.26 | -$ 5.85 | |
| Nov 14, 2025 | -$ 1.95 | -$ 1.75 | -$ 139.86 | |
| Aug 14, 2025 | -$ 2.27 | -$ 1.71 | -$ 454.55 | |
| May 15, 2025 | -$ 3.91 | -$ 2.59 | -$ 297.20 | |
| Mar 31, 2025 | -$ 4.10 | -$ 9.40 | -$ 699.30 | |
| Nov 15, 2024 | -$ 62.30 | -$ 5.85 | -$ 751.75 | |
| Aug 22, 2024 | -$ 122.50 | -$ 139.86 | -$ 1,625.87 | |
| May 14, 2024 | -$ 0.27 | -$ 454.55 | -$ 1,818.18 | |
| Mar 28, 2024 | -$ 0.36 | -$ 297.20 | -$ 1,748.25 | |
| Nov 14, 2023 | -$ 0.43 | -$ 699.30 | -$ 1.87 | |
| Aug 14, 2023 | -$ 0.55 | -$ 751.75 | -$ 2,447.55 | |
| May 15, 2023 | -$ 1,783.22 | -$ 1,625.87 | -$ 2,447.55 | |
| Mar 14, 2023 | -$ 1,398.60 | -$ 1,818.18 | -$ 2,097.90 | |
| Nov 14, 2022 | -$ 2,097.90 | -$ 1,748.25 | -$ 2,797.20 | |
| Aug 15, 2022 | -$ 1,748.25 | -$ 1.87 | -$ 2,097.90 | |
| May 12, 2022 | -$ 2,447.55 | -$ 2,447.55 | -$ 3,496.50 | |
| Mar 30, 2022 | -$ 1.60 | -$ 2,447.55 | -$ 5,244.76 |
ENDRA Life Sciences’s stock was trading at $ 4.64 on Nov 12, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 13, 2026 | | $ 4.64 | ||
| Aug 14, 2026 | -$ 0.63 | $ 4.47 | $ 4.49 | |
| May 18, 2026 | -$ 1.09 | $ 5.05 | $ 5.59 | |
| Mar 31, 2026 | -$ 3.26 | $ 4.68 | $ 4.65 | |
| Nov 14, 2025 | -$ 1.75 | $ 6.57 | $ 6.20 | |
| Aug 14, 2025 | -$ 1.71 | $ 4.38 | $ 4.86 | |
| May 15, 2025 | -$ 2.59 | $ 3.13 | $ 3.23 | |
| Mar 31, 2025 | -$ 9.40 | $ 4.05 | $ 3.92 | |
| Nov 15, 2024 | -$ 5.85 | $ 5.29 | $ 4.17 | |
| Aug 22, 2024 | -$ 139.86 | $ 15.65 | $ 13.87 | |
| May 14, 2024 | -$ 454.55 | $ 509.43 | $ 508.38 | |
| Mar 28, 2024 | -$ 297.20 | $ 1,435.53 | $ 705.43 | |
| Nov 14, 2023 | -$ 699.30 | $ 1,639.75 | $ 1,697.50 | |
| Aug 14, 2023 | -$ 751.75 | $ 2,275.00 | $ 2,012.50 | |
| May 15, 2023 | -$ 1,625.87 | $ 2,450.00 | $ 2,275.00 | |
| Mar 14, 2023 | -$ 1,818.18 | $ 6,562.50 | $ 6,300.00 | |
| Nov 14, 2022 | -$ 1,748.25 | $ 7,665.00 | $ 7,007.00 | |
| Aug 15, 2022 | -$ 1.87 | $ 12,324 | $ 11,641 | |
| May 12, 2022 | -$ 2,447.55 | $ 6,664.00 | $ 6,965.00 | |
| Mar 30, 2022 | -$ 2,447.55 | $ 12,915 | $ 13,650 |
ENDRA Life Sciences released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
ENDRA Life Sciences beat analysts’ expectations during the last earnings period by
